The EPA’s New Clean Air Initiative for Pharma: Who Will Follow Pfizer?

$427.00
Quantity Discounts
1 - 9999
$427.00
1 - 9999
$427.00
1 - 9999
$627.00
On June 23, Pfizer became the first drug company to be penalized under the Environmental Protection Agency’s (EPA) Clean Air Act National Emission Standards for Pharmaceuticals Production, also known as the PharmaMACT (Maximum Achievable Control Technology) standards. The U.S. Department of Justice stated that the nearly $1 million in fines was a “strong message” to drugmakers showing that they need to meet these regulatory requirements to detect and prevent leaking of harmful chemicals.

And that’s not an empty threat.

The fact that this is the first penalty since the regulations took effect in 2002 does not mean there haven’t been any violations — the EPA simply has not been enforcing the regulations … until now!

In fact, experts say it is the standard operating procedure of the EPA to give an industry sector a grace period to get compliant with new regulations. Once a regional office finds a violation, notice goes out to every office in the country to begin looking for violators. The Pfizer case signals that the pharmaceutical industry is now under an EPA National Enforcement Initiative. Every EPA regional office is now charged with checking on the companies in its jurisdiction.

When the EPA shows up at your facility, will you be ready?

In this 90-minute audioconference, attorney Dennis Arfmann will draw on his vast experience defending clients from EPA enforcement to tell attendees what the National Enforcement Initiative means for them, what to expect from the EPA and how to make sure they are ready.

Sign up your entire team to listen in and discover:

  • A detailed explanation of the PharmaMACT regulations, their history and what they mean for drugmakers
  • The top five violations that could cost companies the most
  • How the EPA begins a National Enforcement Initiative and who they’ll most likely go after
  • What the EPA investigators will look for in manufacturing facilities
  • 10 tips for creating compliance procedures and following them
  • What companies can learn from the Pfizer complaint and settlement

Avoid fines, negative press coverage, high repair costs and the expense of potential shutdowns that can result from violations of the regulations.

This audioconference is a must for employees of drug and biologic manufacturers, including:
  • Compliance officers
  • General/corporate counsel
  • Regulatory/legislative affairs professionals
  • Executive management
  • Business development officers
  • International business operations
  • Outside attorneys

Dennis Arfmann is a partner with the law firm Hogan & Hartson and co-chair of the international climate change and clean energy practice. His practice focuses on air quality; hazardous waste and water quality, with particular emphasis on successfully resolving citizen and Environmental Protection Agency (EPA) enforcement actions; citing new energy sources; innovative solutions to cutting-edge issues like regional haze and climate change; and helping resolve complicated regulatory and legislative matters. He has tried more than 100 cases.

Dennis' career includes representing energy companies, refineries and manufacturers in high-profile defense of citizen suits and EPA/state enforcement cases, as well as successful citing and permitting of controversial energy sources, enforcement investigations and litigation throughout the U.S.

Register now!

Date: Wednesday, Aug. 27, 2008
Location: Your office or conference room (no need to travel!)
Time: 1:30 p.m. – 3:00 p.m. EDT
  12:30 p.m. – 2:00 p.m. CDT
  11:30 a.m. – 1:00 p.m. MDT
  10:30 a.m. – 12:00 p.m. PDT
  6:30 p.m. – 8:00 p.m. BST

Gather your team for maximum benefit! Your investment is for one dial-in.

Interested in registering multiple sites?
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
to learn about our special multisite discount.

Check your local time against the times above. (Washington, D.C. is representative of Eastern time.)

Can't make the scheduled date and time? See the 24/7 ENCORE option described below.

Four Cost-Effective Tuition Options
All participants of the live session are eligible to receive a certificate of attendance.

Payment is required by the date of the audioconference. We accept American Express, Visa and MasterCard. Make checks payable to FDAnews.

Or, register by phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600

Cancellations/Substitutions
Audioconference registrations may not be cancelled. Registrants may substitute the 24/7 ENCORE™ audio presentation or the CD/transcript package for the live audioconference at any time. Please contact customer service to make any substitutions. No shows will automatically be shipped the CD/transcript package, including the speaker's presentation. (Additional shipping and handling charges for the CD/transcript package may apply.)